Should Older People Take Melatonin?

Nearly half of adults over 65 report difficulty sleeping — not because they need less rest, but because aging quietly dismantles the body's melatonin-producing machinery. By your 60s, your pineal gland may produce significantly less melatonin than it did at 30, and the timing of that production shifts too. The result: harder to fall asleep, harder to stay asleep, and earlier morning waking. Melatonin supplements offer a rational, low-risk option for many older adults — but the standard doses sold at pharmacies are almost certainly too high, and a handful of common medications change the risk picture in ways worth understanding before you start.

Table of Contents

1. Why Sleep Changes After 60
2. What Happens to Melatonin as You Age
3. What the Evidence Shows: Benefits for Older Adults
4. Getting the Dose Right: Why Less Is More After 60
5. Drug Interactions: What Older Adults Must Know
6. The Absorption Advantage: Getting More from Less
7. Frequently Asked Questions
8. Conclusion
9. Research References

1. Why Sleep Changes After 60

Sleep does not simply become "lighter" with age — its architecture changes in specific, measurable ways. Research published in the Journal of Clinical Sleep Medicine found that sleep maintenance insomnia (waking in the night and struggling to return to sleep) affects 50–70% of elderly insomnia sufferers, compared to 35–60% who have difficulty falling asleep in the first place. This matters clinically because most melatonin studies measure sleep onset latency — but the bigger problem for many older adults is fragmented sleep, not getting to sleep.

The shift in sleep architecture has both physiological and circumstantial drivers. Slow-wave (deep) sleep decreases progressively after age 60, and the circadian rhythm — the 24-hour biological clock — advances, meaning older adults naturally feel sleepy earlier in the evening and wake earlier in the morning. According to a review in Sleep Medicine Clinics, 46% of community-dwelling adults aged 65–74 report insomnia symptoms, with annual new-onset rates running at 3–5% per year. By any measure, this is a widespread clinical problem, not a personal failing.

The practical implication is that sleep problems in older adults are often multifactorial. Pain syndromes, cardiovascular disease, depression, anxiety, and polypharmacy all independently disrupt sleep. A 2022 BMC Public Health cross-sectional study of 5,074 older adults found that approximately 30% slept fewer than the recommended 7 hours per night, and only 10% had discussed sleep with a healthcare professional in the prior year — despite 22% using sleep aids regularly. Melatonin is commonly one of those aids, often self-selected and often at the wrong dose.

2. What Happens to Melatonin as You Age

Melatonin is synthesized and released by the pineal gland, a pea-sized structure deep in the brain that responds to light and darkness signals from the retina. This release follows a precise circadian rhythm: levels rise about 2 hours before habitual bedtime, peak in the middle of the night, and fall sharply before waking. In young adults, peak nocturnal melatonin levels typically reach 100–200 pg/ml. By age 70, those levels may be 20–30% of what they were at 30, and the timing of the peak often shifts earlier — a condition called advanced sleep-wake phase syndrome.

A cross-sectional study cited in a 2018 review in the British Journal of Pharmacology found that the robustness of the circadian system decreases with age, and diminished nocturnal melatonin has been consistently reported in elderly patients — particularly in those with hypertension, coronary disease, and neurodegenerative conditions. This is not incidental: the circadian rhythm in blood pressure is blunted in older adults with insomnia, and poor sleep quality increases the risk of cardiovascular disease and cognitive decline. The decline in melatonin appears to be both a symptom and a driver of this broader deterioration.

The mechanism of decline is primarily structural: the calcification of the pineal gland, which affects approximately 40% of adults by age 40 and increases with age, reduces pinealocyte function. Separately, the retina of older adults transmits weaker light signals to the suprachiasmatic nucleus (the brain's master clock), further impairing the circadian entrainment that drives melatonin release. The NIH notes that melatonin may be more beneficial for older adults specifically because they are more likely to be melatonin-deficient — not because the supplement is inherently superior in this group, but because they have more physiological room for benefit.

3. What the Evidence Shows: Benefits for Older Adults

The clinical evidence for melatonin in older adults is genuinely mixed — which is worth stating plainly rather than glossing over. Overall, the data supports modest but clinically meaningful benefits for sleep onset, with weaker evidence for sleep maintenance. In adults specifically aged 55–80, a summary in American Family Physician reviewing three industry-sponsored RCTs found that prolonged-release melatonin 2 mg reduced sleep onset latency by 15.6 minutes at 3 weeks and 14.5 minutes at 26 weeks compared to placebo. In one of those trials, melatonin doubled the odds of a favorable sleep response (OR = 1.97), with adverse effects similar to placebo at 6.1% vs 5.3%.

A 2025 meta-analysis in Age and Ageing (Oxford Academic) specifically examined adults 65+ with cognitive impairment, pooling 10 RCTs involving 516 participants. Melatonin increased total sleep time by a mean of 12.4 minutes and improved cognitive scores on the Mini-Mental State Examination by 1.8 points — effects described as "approaching clinically important thresholds." Neuropsychiatric symptoms also decreased. These findings are notable because this represents precisely the population where sleep disruption is most clinically consequential, and where the alternatives (benzodiazepines, Z-drugs) carry the greatest risks.

Importantly, melatonin compares favorably to pharmaceutical alternatives for this age group — not because it is more potent, but because it avoids the risks that make those alternatives problematic in older adults:

• No rebound insomnia: a 3-week trial in 170 patients aged 55–93 found no increased sleep disturbance after stopping melatonin, in contrast to benzodiazepine withdrawal
• No dependence: no evidence of tolerance or habituation across trials lasting up to 6 months
• No next-morning impairment at low doses: immediate-release melatonin has a half-life of approximately 45 minutes
• Broad safety profile: the 2023 Clinical Interventions in Aging review found no increase in major cardiovascular events across systematic reviews of melatonin use

 

4. Getting the Dose Right: Why Less Is More After 60

The most consistent finding across melatonin research in older adults is that lower doses work as well as — or better than — higher doses, and that standard OTC doses (5–10 mg) are almost certainly too high. The key reason: a systematic review in Drugs & Aging found that older adults experience a higher elevation of melatonin blood levels from supplementation than younger adults. In other words, a 5 mg tablet produces a much larger spike in an older adult than it does in a 35-year-old — and that spike, sustained well into the following morning, is associated with daytime grogginess and increased fall risk. This is not a theoretical concern: falls are the leading cause of injury-related death in adults 65+.

The clinical literature points consistently toward a starting dose of 0.5–1 mg for adults over 60, titrating up to 2 mg if needed. A 2019 clinical review in Senior Care Pharmacist evaluated doses from 0.5–10 mg across 25 studies and concluded that doses of 1–6 mg appear effective in older adults, with no dose-response relationship clearly established at higher doses. This means that 1 mg may produce equivalent sleep benefit to 5 mg in this population, with significantly less risk of next-day sedation. The practical advice: start at 0.5 mg, use the lowest effective dose, and take it 30–60 minutes before the intended bedtime — not several hours earlier, which can shift the circadian rhythm rather than simply reinforce it.

Formulation matters significantly here. Standard immediate-release tablets hit the bloodstream rapidly, spike to supra-physiological levels, and clear within a few hours — a pattern that does not replicate natural nocturnal melatonin release. Prolonged-release formulations (used in the most encouraging older-adult RCTs) provide a slower, more sustained release that more closely matches the physiological curve. Liquid formulations offer a third option: BioAbsorb's liposomal melatonin uses a graduated dropper that allows precise dosing in increments as small as 0.25 mg — making true low-dose titration practical in a way that conventional tablets simply cannot accommodate.

5. Drug Interactions: What Older Adults Must Know

The average adult over 65 in the United States takes 4–5 prescription medications daily. This creates a meaningful interaction risk for melatonin that does not exist for most younger supplement users. The interactions are not theoretical. The 2023 Clinical Interventions in Aging review identified the following as the most clinically significant categories for older adults:

• Warfarin (and other anticoagulants): A case series at Massachusetts General Hospital found that concurrent melatonin and warfarin use raised INR and prothrombin time in 8 of 10 patients. No life-threatening bleeding was reported, but increased monitoring of coagulation markers is essential if both are taken together.
• Antihypertensives: Melatonin has a blood pressure-lowering effect, which can produce unpredictable combined effects with antihypertensive medications. Specifically, melatonin has been shown to reduce the efficacy of nifedipine (a calcium channel blocker), increasing systolic blood pressure by 6.5 mmHg and diastolic by 4.5 mmHg in one trial.
• Antidepressants (SSRIs and tricyclics): Antidepressants like fluvoxamine and citalopram can increase melatonin levels 2–17x by inhibiting its hepatic metabolism. Given that depression is common in older adults and polypharmacy is the norm, this combination creates a substantial risk of excess sedation. A case of severe sedation has been reported with concurrent melatonin, oxycodone, citalopram, and nortriptyline.

Mayo Clinic further notes that melatonin may impair blood sugar control in people taking diabetes medications, reduce the effectiveness of immunosuppressants, and amplify sedation from CNS depressants (benzodiazepines, opioids, antihistamines). The practical takeaway is clear: melatonin may be available without a prescription, but for an older adult on multiple medications, it requires the same due diligence as any new prescription. A pharmacist review of the full medication list before starting is strongly recommended.

Liver function also affects how melatonin is metabolized. Melatonin is processed almost entirely by hepatic CYP1A2 enzymes, and liver disease reduces clearance — extending the duration of elevated melatonin levels. Older adults with any degree of hepatic impairment should start at the lowest possible dose (0.25–0.5 mg) and monitor for prolonged sedation. Notably, studies have not found a significant increase in major cardiovascular events with melatonin, and there is no evidence of psychological dependence — both positive findings relative to prescription alternatives.

6. The Absorption Advantage: Getting More from Less

For older adults specifically, bioavailability is not just a marketing consideration — it is a clinical variable that directly affects the dosing math. Standard oral melatonin tablets undergo first-pass metabolism in the liver, with only 15–20% of the ingested dose reaching systemic circulation. This low bioavailability is one reason manufacturers sell 5–10 mg tablets: to overcome the metabolic barrier. The problem is that those doses produce highly variable blood levels, and in older adults — who already process melatonin more slowly — the result is often supra-physiological concentrations that persist through the morning hours.

Liposomal delivery bypasses first-pass metabolism by encapsulating melatonin in phospholipid vesicles that fuse directly with cell membranes. BioAbsorb's Liposomal Liquid Melatonin achieves 80–95% bioavailability, compared to 15–20% for standard tablets, with onset in 15–30 minutes versus 60–90 minutes for conventional forms. For an older adult seeking a 0.5–1 mg effective dose, this means taking a fraction of the amount typically sold in tablet form — which directly reduces the risk of the supra-physiological spikes that drive next-day grogginess and fall risk. At $29.99 for 100 ml (100 servings at the standard dropper dose), the graduated dropper format makes precise low-dose titration practical in a way that tablets simply cannot match.

BioAbsorb's formulation is manufactured in a Health Canada-approved, GMP-certified Canadian facility, third-party tested with every batch and COAs available on request. The product is non-GMO, vegan, gluten-free, and free of artificial flavours and colours — all relevant considerations for older adults who tend to be more sensitive to excipients and additives. The 1.5 mg per full dropper dose and the 0.25 mg graduated increments make it the most dosage-precise melatonin option currently available for older adults who want to follow the clinical recommendation to start low and titrate slowly.

Frequently Asked Questions

Is melatonin safe for people over 70?

At low doses (0.5–2 mg), the evidence suggests a favorable safety profile for adults over 65 and 70. The key caveats are polypharmacy (check for interactions with warfarin, antihypertensives, and antidepressants before starting), liver function (melatonin clearance is slower with hepatic impairment), and fall risk from any residual morning sedation if dosing is too high. High doses (5–10 mg) are not appropriate for most adults over 70 and are not more effective than low doses at improving sleep in this group.

What is the right melatonin dose for adults over 65?

The clinical consensus points to 0.5–2 mg as the effective range for most adults 65+, with a starting dose of 0.5 mg. The 2014 Drugs & Aging systematic review recommends using the lowest effective dose of immediate-release melatonin to best mimic physiological circadian rhythm, specifically to avoid the prolonged supra-physiological blood levels seen with higher doses in this age group. Starting at 0.5 mg and titrating up over 3–5 nights is the most evidence-aligned approach.

Can melatonin interfere with my blood pressure medication?

Yes — this is one of the more important interactions for older adults to be aware of. Melatonin has an independent blood-pressure-lowering effect, which can combine unpredictably with antihypertensive drugs. Specifically, melatonin has been shown to reduce the efficacy of nifedipine, a widely used calcium channel blocker, raising blood pressure in those taking it. If you take any blood pressure medication, discuss melatonin use with your prescriber and monitor your blood pressure in the first week after starting.

Does melatonin help with sleep maintenance insomnia (waking in the night)?

The evidence for sleep maintenance is weaker than for sleep onset in older adults. Melatonin's primary mechanism — shifting and reinforcing circadian timing — works most clearly on sleep onset latency. Some research in adults aged 55–80 shows modest improvements in sleep architecture and sleep quality overall, but for sleep maintenance specifically, addressing underlying contributors (pain, nocturia, anxiety, medications) is typically more effective. Melatonin can be a useful adjunct but is unlikely to resolve fragmented sleep on its own.

Is it safe to take melatonin every night long-term?

The evidence on long-term melatonin use in older adults is limited, with most trials running 3–26 weeks. Within that window, the safety profile is favorable with no evidence of dependence or withdrawal effects. No rebound insomnia has been found after stopping. For long-term use, the main unknowns are chronic effects on cardiovascular and endocrine function. The prudent approach is to use the lowest effective dose, reassess periodically, and take occasional breaks to determine whether the supplement is still needed.

Should I take melatonin if I have dementia?

Dementia-related sleep disturbances are among the most difficult sleep problems to treat, and most pharmacological options carry significant risks in this population. A 2025 meta-analysis in Age and Ageing found modest improvements in total sleep time (+12.4 minutes) and cognition in 10 RCTs of adults 65+ with cognitive impairment. However, some expert guidelines recommend against melatonin in elderly patients with severe dementia, as the evidence is not conclusive. Speak with a geriatric physician before using melatonin in this context.

Conclusion

For most healthy adults over 60 dealing with difficulty falling asleep, melatonin is a rational, low-risk first option — particularly given the significant risks of benzodiazepines and Z-drugs in this population. The evidence supports real but modest benefits for sleep onset, and a favorable safety profile at low doses. The most important things to get right: start at 0.5–1 mg (not 5 mg), choose a formulation that allows precise dosing and provides consistent bioavailability, and check for interactions with any existing medications before starting. BioAbsorb's liposomal liquid melatonin — with its graduated dropper, high bioavailability, and Health Canada-certified manufacturing — is designed precisely for the clinical needs of this age group.

Research References

1. Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature. Drugs & Aging, Vol. 31 (2014). Concluded that older adults show a higher melatonin blood level elevation than younger adults from the same dose, and recommended using the lowest possible immediate-release dose to best mimic physiological circadian rhythm and avoid prolonged supra-physiological blood levels.
2. Current Insights into the Risks of Using Melatonin as a Treatment for Sleep Disorders in Older Adults. Clinical Interventions in Aging, Vol. 18 (2023). Comprehensive narrative review of melatonin safety in adults 65+; identified drug interactions with warfarin, antihypertensives, and antidepressants as primary clinical risks; found no evidence of dependence, withdrawal, or major cardiovascular events.
3. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Current Medical Research and Opinion, Vol. 23 (2007). Randomized double-blind placebo-controlled trial (n=354) demonstrating significant improvements in sleep quality, morning alertness, and sleep onset latency with prolonged-release 2 mg melatonin; no withdrawal effects on cessation.
4. Melatonin to Treat Insomnia in Older Adults. American Family Physician, Vol. 104 (2021). Evidence synthesis of multiple RCTs: prolonged-release melatonin reduced sleep onset latency by 15.6 minutes at 3 weeks and 14.5 minutes at 26 weeks vs placebo; doubled the odds of a favorable sleep response (OR = 1.97) in adults 65–80.
5. Melatonin for sleep and cognitive outcomes in older adults with cognitive impairment: a meta-analysis of randomised controlled trials. Age and Ageing, Vol. 54 (2025). Meta-analysis of 10 RCTs (n=516) in adults 65+ with cognitive impairment: melatonin increased total sleep time by 12.4 minutes and improved MMSE scores by 1.8 points; neuropsychiatric symptoms decreased.
6. Sleep in the Aging Population. Sleep Medicine Clinics, Vol. 12 (2017). Population-level review: insomnia symptoms prevalence approaches 50% in adults aged 65+; annual new-onset rate 3–5%; sleep complaints are not an inherent part of aging but reflect multifactorial geriatric health conditions.
7. Insomnia in the Elderly: A Review. Journal of Clinical Sleep Medicine (PMC, 2018). Comprehensive review of insomnia epidemiology in adults 65+: prevalence of insomnia symptoms 30–48%; insomnia disorder 12–20%; 93% have one or more comorbid conditions; sleep maintenance insomnia (50–70%) is the predominant subtype.
8. Optimal Melatonin Dose in Older Adults: A Clinical Review of the Literature. Senior Care Pharmacist, Vol. 34 (2019). Clinical review evaluating 0.5–10 mg doses across 25 studies; concluded doses of 1–6 mg appear effective in older adults with no clear dose-response at higher doses; recommended starting low due to variable absorption in this population.
9. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. British Journal of Pharmacology, Vol. 175 (2018). Established that the robustness of the circadian system decreases with age; diminished nocturnal melatonin documented in elderly patients with hypertension, coronary disease, and neurodegenerative conditions; exogenous melatonin improves circadian rhythm amplitude and alignment.
10. Melatonin: What You Need to Know. National Center for Complementary and Integrative Health — NIH (2022). NIH institutional guidance on melatonin use; notes that melatonin may be more beneficial for older adults who are melatonin-deficient; advises physician consultation before use in adults 65+.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.